QUASAR trial showed Eylea HD matched vision gains of standard Eylea with less frequent dosing. BofA cuts Regeneron price target to $547, maintains Underperform rating. China’s new tariffs just ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron’s proposal to add additional ...

The FDA has granted Priority Review status to Regeneron’s and Bayer’s supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) injection 8 mg. The application seeks to expand use ...

TARRYTOWN, N.Y. - The U.S. Food and Drug Administration (FDA) has begun Priority Review of Regeneron Pharmaceuticals’ supplemental Biologics License Application for EYLEA HD (aflibercept ...

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which ...

The CRL did not identify any issues with the safety or efficacy of EYLEA HD in its approved indications and dosing regimens. The FDA did not agree with Regeneron's proposal to add additional extended ...

Regeneron (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing a supplemental biologics license application ((sBLA)) for its eye disease drug Eylea HD injection, 8 mg, to expand its ...

On April 17, Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for EYLEA HD ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology conditions and is a biosimilar of Regeneron's Eylea (aflibercept). Biocon ...